First quarter: a record result and awards to employees

20 April 2021 - Corporate -

Breaking through 3 million euro in turnover, ASA marks an excellent result for the first 3 months of activity of 2021 thanks to a significant increase in the sales of its therapies for the human and veterinary sector worldwide.

The performance is the result of the strategy developed and applied consistently throughout 2020, during which the company, despite having drastically reduced its production activity during certain moments of the year without in any case ever suspending it, continued to invest in training and in the implementation of its own sales and after-sales network. This intervention plan allowed closing the annus horribilis in the black, thanks also to wise choices in managing resources (layoffs for short periods and with diversified methods by department, smart working, etc.).

Despite the complexity of the economic period, ASA has also decided to allocate a greater amount than ever distributed in previous years towards the partial relief of the contraction in remuneration caused by the COVID-19 redundancy fund and to distribute additional bonuses linked to sales results as well as to the number of webinars and online training sessions held in 2020. The latter activities contributed to starting 2021 with a double-digit percentage growth, as confirmed by the excellent Asian performances, South Korea in the lead, and by the European ones (France and England in first place).
The response of the Italian market has also been meaningful: + 15% on the target budget for the first quarter of 2021 for sales of rehabilitation and physiotherapy devices in the human and vet fields.

“We have ended a difficult 2020 by investing and presenting new Therapeutic Solutions, now we are looking to the near future with great attention, aware that there is a great deal to develop in order to create a recovery that is solid, structured and continuous" comments Roberto Marchesini, ASA’s General Manager.

You might also be interested in ...

See all articles

press - 20/04/2021
The first quarter of 2021 marks a historic record for ASA: breaking through the milestone of 3 million euros, the company registers the best performance of the last 5 years in the first 3 months of...
MLS training at Thai University
news - 29/03/2021
Two universities, two lectio magistralis, one protagonist: MLS® Laser Therapy and its devices of excellence. The two lectures were hosted by the University of Phayao in northern Thailand and by the...
M6 laser & pain management
news - 21/01/2021
“Following our direct experience, we confirm the conclusions reached in America in relation to the value of MLS® for treating interstitial pneumonia caused by the virus. Its action consists in...
ASA tema @ ArabHealth 2024
News - 15/02/2024
In order to provide maximum visibility and the best dissemination of the strengths of its Therapeutic Solutions, the company preceded its attendance at the fair (Dubai, 29th January – 1st February)...
Neuropatic pain
Blog - 05/02/2024
The clinical research* conducted by Dr. Yosifova, as published in the Journal of IMAB, highlights the promising role of ASA's M6 robotic laser in mitigating neuropathic pain associated with diabetic...
ASA @ Medica 2023
News - 02/12/2023
The occasion to best celebrate ASA’s 40th birthday could only be Medica. The fair in Düsseldorf in fact represented the occasion to share this important milestone with both loyal and new customers.